Biased Evaluation in Cancer Drug Trials—How Use of Progression-Free Survival as the Primary End Point Can Mislead
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- May 1, 2022
has subject area
- 1112 Oncology and Carcinogenesis (FoR)
- 1117 Public Health and Health Services (FoR)
- Antineoplastic Agents (MeSH)
- Disease-Free Survival (MeSH)
- Humans (MeSH)
- Neoplasms (MeSH)
- Progression-Free Survival (MeSH)
published in
- JAMA Oncology Journal